Trade Report: The Brean Capital Begins Coverage on Heron Therapeutics Inc. (HRTX)

The Brean Capital Begins Coverage on Heron Therapeutics Inc. (HRTX)

Brean Capital began coverage on shares of Heron Therapeutics Inc. (NASDAQ:HRTX) in a research report report published on Tuesday. The firm issued a buy rating and a $41.00 target price on the biotechnology company’s stock.

A number of other brokerages also recently commented on HRTX. Zacks Investment Research downgraded Heron Therapeutics from a hold rating to a sell rating in a research note on Wednesday, August 3rd. Leerink Swann restated a buy rating and issued a $33.00 target price on shares of Heron Therapeutics in a research note on Sunday, October 2nd. Cantor Fitzgerald restated a buy rating and issued a $41.00 target price on shares of Heron Therapeutics in a research note on Wednesday, August 3rd. Lake Street Capital restated a buy rating and issued a $45.00 target price on shares of Heron Therapeutics in a research note on Tuesday, September 6th. Finally, Jefferies Group decreased their target price on Heron Therapeutics from $46.00 to $40.00 and set a buy rating for the company in a research note on Monday, October 3rd. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Heron Therapeutics presently has an average rating of Buy and a consensus target price of $42.29.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 16.83 on Tuesday. Heron Therapeutics has a one year low of $15.13 and a one year high of $31.32. The firm’s 50-day moving average price is $18.62 and its 200-day moving average price is $18.90.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. Equities research analysts expect that Heron Therapeutics will post ($4.39) earnings per share for the current year.

In related news, insider Robert Rosen sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the sale, the insider now owns 102,640 shares of the company’s stock, valued at $2,391,512. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 20.31% of the company’s stock.

Large investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its stake in shares of Heron Therapeutics by 28.2% in the first quarter. Franklin Resources Inc. now owns 7,523,278 shares of the biotechnology company’s stock valued at $142,869,000 after buying an additional 1,653,008 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares during the last quarter. VHCP Management II LLC purchased a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $7,708,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $734,000. Finally, Panagora Asset Management Inc. boosted its stake in shares of Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock valued at $4,660,000 after buying an additional 116,461 shares during the last quarter.

About Heron Therapeutics

Related posts

Leave a Comment